Samuele Cazzamalli
Overview
Explore the profile of Samuele Cazzamalli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
492
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Georgiev T, Puglioli S, Principi L, Gilardoni E, Pellegrino C, Bassi G, et al.
Mol Cancer Ther
. 2025 Mar;
PMID: 40034039
Prostate Specific Membrane Antigen (PSMA) is a transmembrane glycoprotein that is over-expressed on the surface of cancerous prostate cells both in primary tumors and in metastases. Small organic ligands targeting...
2.
Bocci M, Principi L, Gilardoni E, Neri D, Cazzamalli S, Galbiati A
Bioconjug Chem
. 2024 Dec;
36(1):15-19.
PMID: 39718420
OncoFAP is an ultrahigh affinity ligand of fibroblast activation protein (FAP), a tumor-associated antigen overexpressed in the stroma of the majority of solid tumors. OncoFAP has been previously implemented as...
3.
Galbiati A, Bocci M, Neri D, Cazzamalli S
Eur J Nucl Med Mol Imaging
. 2024 Nov;
52(4):1399-1405.
PMID: 39528843
Purpose: Lu-OncoFAP-23 is a novel FAP-targeted radioligand therapeutic (RLT) with high and prolonged tumor residence time and promising preclinical efficacy. In this work, we investigated the correlation between the injected...
4.
Galbiati A, Bocci M, Ravazza D, Mock J, Gilardoni E, Neri D, et al.
J Nucl Med
. 2024 Sep;
65(10):1604-1610.
PMID: 39266289
Fibroblast activation protein (FAP) is abundantly expressed in the stroma of most human solid tumors. Clinical-stage radiolabeled FAP ligands are increasingly used as tools for the detection of various cancer...
5.
Galbiati A, Bocci M, Gervasoni S, Prodi E, Malloci G, Neri D, et al.
J Med Chem
. 2024 Jul;
67(15):13392-13408.
PMID: 39079004
Fibroblast activation protein (FAP) is a protein biomarker widely expressed in most solid human malignancies of epithelial origin. In recent years, a number of FAP-targeted small organic radioligands, including OncoFAP,...
6.
Puglioli S, Fabbri M, Comacchio C, Alvigini L, De Luca R, Oehler S, et al.
Bioconjug Chem
. 2024 Jul;
35(7):1033-1043.
PMID: 38963407
DNA-Encoded Libraries (DELs) allow the parallel screening of millions of compounds for various applications, including discovery or affinity maturation campaigns. However, library construction and HIT resynthesis can be cumbersome, especially...
7.
Rotta G, Puca E, Cazzamalli S, Neri D, Dakhel Plaza S
Bioconjug Chem
. 2024 Jun;
35(8):1075-1088.
PMID: 38885090
Cytokines are small proteins that modulate the activity of the immune system. Because of their potent immunomodulatory properties, some recombinant cytokines have undergone clinical development and have gained marketing authorization...
8.
Lucaroni L, Oehler S, Georgiev T, Muller M, Bocci M, De Luca R, et al.
Chem Sci
. 2024 May;
15(18):6789-6799.
PMID: 38725500
Prostate-specific membrane antigen (PSMA) is a tumor-associated protein that has been successfully targeted with small organic ligands and monoclonal antibodies. Pluvicto™ is a PSMA-targeted radioligand therapeutic (RLT) recently approved by...
9.
Muller M, Lucaroni L, Favalli N, Bassi G, Neri D, Cazzamalli S, et al.
J Med Chem
. 2024 May;
67(10):8247-8260.
PMID: 38716576
Prostate-specific membrane antigen (PSMA)-targeted radio ligand therapeutics (RLTs), such as [Lu]Lu-PSMA-617 (Pluvicto), have been shown to accumulate in salivary glands and kidneys, potentially leading to undesired side effects. As unwanted...
10.
Georgiev T, Principi L, Galbiati A, Gilardoni E, Neri D, Cazzamalli S
Eur J Nucl Med Mol Imaging
. 2024 Apr;
51(8):2332-2337.
PMID: 38563883
Purpose: Pluvicto™ ([Lu]Lu-PSMA-617), a radioligand therapeutic targeting prostate-specific membrane antigen (PSMA), has been recently approved for the treatment of metastatic castration-resistant prostate cancer (mCRPR). The drug suffers from salivary gland...